Partnership combines Mobilicom's groundbreaking OS3 cybersecurity software with ARK's made-in-the- USA, BLUE UAS listed, NDAA compliant, NVIDIA AI-driven hardware ARK joins Mobilicom's booth at XPONENTIAL 2025, a gathering of global leaders and end users in the uncrewed systems and robotics industry, to feature the companies' upcoming joint products First product expected to launch H2 2025 Both companies have products on the Blue UAS Framework, which provides a prestigious shortlist of rigorously vetted pro ...

Core Points - I-Mab, a U.S.-based global biotech company, focuses on developing precision immuno-oncology agents for cancer treatment [1][2] - The management team of I-Mab will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025, discussing clinical progress on its lead program, givastomig [1][2] - New data on givastomig has been accepted for a Mini Oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, scheduled for July 2, 2025, in Barcelona, Spain [2] Company Information - I-Mab is headquartered in Rockville, Maryland, and has operations in Short Hills, New Jersey [2] - The company is publicly traded on NASDAQ under the ticker IMAB [1][2] - For more information, I-Mab's website and social media channels are available [2]

Core Insights - Helius Medical Technologies, Inc. will present the final results of the PoNSTEP study, which confirms the efficacy of the Portable Neuromodulation Stimulator (PoNS) device for improving gait in individuals with multiple sclerosis (MS) [1][2] - The study highlights a statistically significant relationship between adherence to PoNS therapy and improvement in gait, indicating that consistent use leads to sustained benefits [3][4] Study Overview - The PoNSTEP study was a three-phase, real-world therapeutic experience designed to evaluate the impact of adherence on gait deficits and long-term outcomes in MS patients [3][8] - Participants underwent two weeks of supervised therapy, followed by 12 weeks of combined clinic and at-home use, concluding with a six-month follow-up to assess the durability of improvements [3][9] Key Findings - Stronger adherence to PoNS therapy resulted in better therapeutic outcomes, with highly adherent participants achieving over 6 points improvement in their Dynamic Gait Index (DGI) scores during the first 14 weeks [4][5] - More than 95% of participants maintained their level of improvement six months post-treatment, demonstrating the durability of the therapy's effects [5][7] Clinical Implications - The study provides evidence of the effectiveness of neuromodulation and neuroplasticity in rehabilitating gait deficits in MS patients, marking a significant advancement in treatment options for this population [7][10] - PoNS therapy is now accessible through insurance via the U.S. Department of Veterans Affairs and Department of Defense, with some commercial healthcare providers beginning to reimburse the device [7][12] About PoNS Device - The Portable Neuromodulation Stimulator (PoNS) is a non-implantable device that delivers neurostimulation through a mouthpiece, used in conjunction with physical rehabilitation exercises to improve balance and gait in MS patients [12][14] - The device is indicated for short-term treatment of gait deficits due to mild-to-moderate MS symptoms and is prescribed for patients aged 22 and older [12][13]

DETROIT, May 20, 2025 (GLOBE NEWSWIRE) -- DT Midstream, Inc. (NYSE: DTM) announced that it has achieved an investment grade rating with two agencies: With investment grade ratings from these two credit agencies, DTM expects an improvement in liquidity and reduced interest expense. "Achievement of an investment grade credit rating was a strategic goal we had since we became a standalone public company," said David Slater, President and CEO. "The ratings upgrades are a recognition of the strength of our balan ...

- BPL-003 was well-tolerated and patients were able to be discharged within an average time of less than two hours after dosing A single dose of BPL-003 induced rapid and long-lasting antidepressant effects, with a mean MADRS (Montgomery-Asberg Depression Rating Scale) reduction of 18 points from baseline observed the day after dosing, a mean MADRS reduction of 19 points from baseline observed one month after dosing, and a mean MADRS reduction of 18 points from baseline observed three months after dosing. T ...

- Combining these two highly complementary businesses aims to create a global leader in the production of critical and strategically important materials, including electronic gases such as helium, various fluorinated products and isotopically enriched gases. - Combination is expected to create a vertically and horizontally integrated supply chain with significant geographic and customer overlap. Substantial synergies expected from 2026. - Transaction is expected to be highly accretive to 2026 anticipated EP ...

VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Apollo Silver Corp. ("Apollo" or the "Company") (TSX.V: APGO, OTCQB: APGOF, Frankfurt: 6ZF0) is pleased to announce it has acquired 2,215 hectares ("ha") of highly prospective claims contiguous to its Waterloo property at its Calico Silver Project ("Calico" or "Calico Project"). The newly acquired claims herein referred to as the Mule claims comprise 415 lode mining claims, and have been acquired from LAC Exploration LLC ("LAC"), a wholly- owned ...

AS Tallink Grupp (registration code 10238429, location and address at Sadama 5, 10111 Tallinn) held its Annual General Meeting of Shareholders on 20 May 2025 at 11 AM at the conference centre of Tallink SPA & Conference Hotel, at the address Sadama 11a, Tallinn. 66 shareholders were registered as attending at the Annual General Meeting of Shareholders, who owned 567,914,814 votes/shares (the amount of represented share capital 266,919,962.58 EUR), forming 76.38% of AS Tallink Grupp share capital. Resolutio ...

The annual general meeting of VOW ASA has today approved all of the proposed resolutions in the notice of the general meeting dated 29 April 2025. The minutes from the general meeting are enclosed as appendices to this notice. For more information, please contact: Cecilie Brænd Hekneby, CFO, Vow ASATel: +47 99 29 38 26Email: cecilie.hekneby@vowasa.com About Vow ASA Vow and its subsidiaries Scanship, C.H. Evensen and Etia are passionate about preventing pollution. The company's world leading solutions conv ...

Drilling Intersects Wide Zones of Higher-Grade Gold Mineralization at the Boin Gold Deposit VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Newcore Gold Ltd. ("Newcore" or the "Company") (TSX-V: NCAU, OTCQX: NCAUF) is pleased to announce additional drill results from the 35,000-metre drill program underway at the Company’s 100% owned Enchi Gold Project ("Enchi" or the "Project") in Ghana. Shallow Reverse Circulation ("RC") drilling at the Boin Gold Deposit ("Boin") intersected multiple wide zo ...